Study of IMC-002 for active lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with systemic lupus erythematosus (SLE) for at least 12 weeks before joining the study.
- Your lupus must be active, with a SLEDAI-2K score of 8 or higher (this is a measure of disease activity, not counting headache or fever).
- You must have active skin lupus (with a CLASI score of at least 2) and at least one BILAG-2004 organ system score of A (severe) or two B scores (moderate).
- You must be on at least one standard lupus treatment, like prednisone, hydroxychloroquine, or an immunosuppressant.
- You must not have active lupus nephritis (kidney inflammation) or central nervous system lupus.
- You cannot have other autoimmune diseases, serious uncontrolled medical conditions, active infections, or a history of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
This study is testing an experimental medicine called PF-08154225 to see if it can help treat several autoimmune conditions, including rheumatoid arthritis, lupus, and related disorders. It might reduce disease activity or symptoms in people who have not found relief from other treatments.
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.